Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Brain Neoplasms 3Neoplasm Metastasis 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Oligodendroglioma 1Gliosarcoma 1Glioblastoma 1Central Nervous System Neoplasms 1Breast Neoplasms 1Astrocytoma 1Adenocarcinoma of Lung 1

Interventions

Radiotherapy 122Temozolomide 110Carboplatin 53Filgrastim 46Vincristine 43Etoposide 39Cyclophosphamide 37Chemotherapy, Adjuvant 37Cisplatin 36Carmustine 32Irinotecan 27Peripheral Blood Stem Cell Transplantation 25Magnetic Resonance Spectroscopy 24Lomustine 22Thiotepa 21Methotrexate 20Granulocyte Colony-Stimulating Factor 18Procarbazine 16Bevacizumab 16Surgical Procedures, Operative 15O(6)-benzylguanine 14etoposide phosphate 13Drug Therapy 13Topotecan 12Paclitaxel 12Ifosfamide 12Thalidomide 11Radiation 11sargramostim 10Specimen Handling 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Central Nervous System Neoplasms × efaproxiral × Clear all
NCT00005855 2013-06-21

Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant Glioma

National Cancer Institute (NCI)

Phase 1/2 Completed
48 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡